{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:30:34Z","timestamp":1781235034626,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-511x-13-35","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T04:01:29Z","timestamp":1392696089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats"],"prefix":"10.1186","volume":"13","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012, 11: 367-383. 10.1038\/nrd3699","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl","key":"1038_CR2","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH: PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009, 50 (Suppl): S172-S177.","journal-title":"J Lipid Res"},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derr\u00e9 A, Vill\u00e9ger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34: 154-156. 10.1038\/ng1161","journal-title":"Nat Genet"},{"key":"1038_CR4","first-page":"901","volume":"59","author":"NQ Wu","year":"2013","unstructured":"Wu NQ, Guo YL, Xu RX, Liu J, Zhu CG, Jiang LX, Li JJ: Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. Clin Lab. 2013, 59: 901-907.","journal-title":"Clin Lab"},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006, 354: 1264-1272. 10.1056\/NEJMoa054013","journal-title":"N Engl J Med"},{"key":"1038_CR6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, Laufs U: Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013, 62: 1401-1408. 10.1016\/j.jacc.2013.07.056","journal-title":"J Am Coll Cardiol"},{"key":"1038_CR7","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1194\/jlr.M008144","volume":"5","author":"G Welder","year":"2010","unstructured":"Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010, 5: 2714-2721.","journal-title":"J Lipid Res"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","volume":"58","author":"Z Awan","year":"2012","unstructured":"Awan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, Ridker PM, Genest J: Rosuvastatin, proprotein convertase Subtilisin\/Kexin type 9 concentrations, and LDL cholesterol response: the JUPITER Trial. Clin Chem. 2012, 58: 183-189. 10.1373\/clinchem.2011.172932","journal-title":"Clin Chem"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","volume":"2","author":"F Raal","year":"2013","unstructured":"Raal F, Panz V, Immelman A, Pilcher G: Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013, 2: e000028-","journal-title":"J Am Heart Assoc"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ: Atorvastatin increases human serum levels of proprotein Convertase subtilisin\/kexin type 9. J Lipid Res. 2008, 49: 394-398.","journal-title":"J Lipid Res"},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004, 24: 1454-1459. 10.1161\/01.ATV.0000134621.14315.43","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","volume":"361","author":"AJ Taylor","year":"2009","unstructured":"Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009, 361: 2113-2122. 10.1056\/NEJMoa0907569","journal-title":"N Engl J Med"},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM: Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21, 000 subjects from 27 clinical trials. Atherosclerosis. 2012, 223: 251-261.","journal-title":"Atherosclerosis"},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"e60095","DOI":"10.1371\/journal.pone.0060095","volume":"8","author":"HK Berthold","year":"2013","unstructured":"Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I: Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One. 2013, 8: e60095- 10.1371\/journal.pone.0060095","journal-title":"PLoS One"},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1194\/jlr.M013664","volume":"52","author":"B Ason","year":"2011","unstructured":"Ason B, Tep S, Davis HR, Xu Y, Tetzloff G, Galinski B, Soriano F, Dubinina N, Zhu L, Stefanni A, Wong KK, Tadin-Strapps M, Bartz SR, Hubbard B, Ranalletta M, Sachs AB, Flanagan WM, Strack A, Kuklin NA: Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res. 2011, 52: 679-687. 10.1194\/jlr.M013664","journal-title":"J Lipid Res"},{"key":"1038_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","volume":"101","author":"Z Lu","year":"2008","unstructured":"Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Li S, : Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008, 101: 1689-1693. 10.1016\/j.amjcard.2008.02.056","journal-title":"Am J Cardiol"},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/07853891003652534","volume":"42","author":"JJ Li","year":"2010","unstructured":"Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC, : Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med. 2010, 42: 231-240. 10.3109\/07853891003652534","journal-title":"Ann Med"},{"key":"1038_CR18","volume-title":"Cochrane Database Syst Rev","author":"ZL Liu","year":"2011","unstructured":"Liu ZL, Liu JP, Zhang AL, Wu Q, Ruan Y, Lewith G, Visconte D: Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011, 7: CD008305,"},{"key":"1038_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","volume":"150","author":"DJ Becker","year":"2009","unstructured":"Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009, 150: 830-839. 10.7326\/0003-4819-150-12-200906160-00006","journal-title":"Ann Intern Med"},{"key":"1038_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40261-013-0129-2","volume":"33","author":"YL Guo","year":"2013","unstructured":"Guo YL, Liu J, Xu RX, Zhu CG, Wu NQ, Jiang LX, Li JJ: Short-term impact of low-dose atorvastatin on serum proprotein convertase Subtilisin\/Kexin type 9. Clin Drug Investig. 2013, 33: 877-883. 10.1007\/s40261-013-0129-2","journal-title":"Clin Drug Investig"},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, : Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012, 380: 2007-2017. 10.1016\/S0140-6736(12)61770-X","journal-title":"Lancet"},{"key":"1038_CR22","first-page":"163","volume":"120","author":"J Davignon","year":"2009","unstructured":"Davignon J, Dubuc G: Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc. 2009, 120: 163-173.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"1038_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14779072.6.4.447","volume":"6","author":"HE Bays","year":"2008","unstructured":"Bays HE, Neff D, Tomassini JE, Tershakovec AM: Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008, 6: 447-470. 10.1586\/14779072.6.4.447","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1038_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2006.11.031","volume":"122","author":"JJ Li","year":"2007","unstructured":"Li JJ, Wang Y, Nie SP, Li YS, Huang Y, Hui RT: Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feeling in patients with cardiac syndrome X. Int J Cardiol. 2007, 122: 82-84. 10.1016\/j.ijcard.2006.11.031","journal-title":"Int J Cardiol"},{"key":"1038_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R: Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012, 380: 29-36. 10.1016\/S0140-6736(12)60771-5","journal-title":"Lancet"},{"key":"1038_CR26","first-page":"1135","volume":"4","author":"S Poirier","year":"2013","unstructured":"Poirier S, Mayer G: The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013, 4: 1135-1148.","journal-title":"Drug Des Devel Ther"},{"key":"1038_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012, 366: 1108-1118. 10.1056\/NEJMoa1105803","journal-title":"N Engl J Med"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-13-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T19:39:13Z","timestamp":1630611553000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-13-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,18]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-13-35","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,18]]},"assertion":[{"value":"12 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}